Double-hit lymphoma (DHL) is among the most aggressive and chemoresistant lymphoma subtypes.
Western blot analysis
DHL cells were lysed on ice in CelLytic™ MT Cell Lysis Reagent (Sigma) supplemented with protease and phosphatase inhibitors. Protein concentration was determined with Pierce™ BCA Protein Assay Kit (Thermo Fisher). Protein lysates were resolved on SDS-PAGE gels and transferred to PVDF membranes. The following antibodies were used for the Western blot analysis: MYC, cleaved PARP, Caspase 3, BCL2, XPO1, MCL1, BIM, BCL-XL, Lamin B1, and GAPDH (Cell Signaling); MYC (Abcam); β -Tubulin and β -Actin (Proteintech).
Cellular Fractionation and quantitative real-time PCR
Cytoplasmic and nuclear RNA were isolated and purified using the RNA Subcellular Isolation Kit (Active Motif) following the manufacturer's protocol. RNA binding and purification was performed using RNeasy Mini Kit (Qiagen). Total RNA was extracted with RNeasy Mini Kit (Qiagen). cDNA was synthesized using the Verso cDNA Synthesis Kit (Thermo Scientific) according to the manufacturer's instructions. qPCR analysis was performed on 7500 Real Time PCR System using SYBR Green (Applied Biosystems). Transcript levels were normalized to GAPDH, and relative gene expression was determined with ddCt method. Primer sequences are available upon request.
Flow cytometry
The PE Annexin-V Apoptosis Detection Kit (BD Biosciences) was used to detect apoptosis following manufacturer's instruction. Briefly, cells were suspended in 150 μ l of binding buffer and mixed with 5 μ l of FITC-conjugated Annexin-V and 7-AAD, followed by incubation at room temperature for 15 min in the dark. The stained cells were analyzed using a BD FACS Fortessa flow cytometer (BD Bioscience). All flow cytometric data were analyzed with Flowjo software (Tree Star).
Immunohistochemistry
Mice were treated for five days. Subsequently, spleen tumors were collected, formalin-fixed, and paraffin-embedded. 4 micrometer thick sections were subjected to H&E and immunohistochemistry staining. For IHC, MYC (Abcam, ab32072), Ki67 (Abcam, ab16667), and Cleaved caspase 3 (CST, 9661) antibodies were used. Pictures were taken with 40x objectives on a Leica DMi8 microscope.
In vivo therapeutic studies
Animal studies and experimental protocols were approved by Institutional Animal Care and Use daily oral gavage with ABT199 (50mg/kg) and KPT8602 (7.5mg/kg) for 5 successive days, followed by 2 days off for three weeks. ABT199 tablets were dissolved in water by sonication; KPT8602 was dissolved in 0.5% methylcellulose plus 1% Tween-80 as reported [13] [14] [15] 
Results:

XPO inhibition abrogates MYC protein expression and induces apoptosis in DHLs
First, we examined whether XPO1 inhibition affects MYC protein levels in DHL cell lines. Treatment with the XPO1 inhibitor, KPT8602, led to a significant decrease in MYC protein expression in the majority of DHLs in our diverse cell line panel (Fig 1A) . Three DHL cell lines (SU-DHL4, Toledo, and SU-DHL6) were selected to further examine MYC regulation by XPO1 inhibitors [16] . Treatment with two specific XPO1 inhibitors, KPT330 and KPT8602, points to a dose-and time-dependent downregulation of MYC protein expression in all three cell lines (Fig 1B-C, and Supplementary Fig   S1) . These results establish that XPO1 inhibition effectively abrogates MYC protein expression in DHL tumor cells. Decreased MYC protein level was followed by changes in gene expression of MYC downstream targets (Fig 1D-E) . Genes known to be upregulated by MYC, including ENO1, APEX1, RPL3, RPS5, SRM and nucleolin [17] , were significantly downregulated upon XPO1 inhibition. In contrast, genes reportedly suppressed by MYC, such as HBP1, P27, and P15, were upregulated upon treatment with XPO1 inhibitors. The abrogation of MYC protein expression by XPO1 inhibition was accompanied by induction of apoptosis, as manifested by the cleavage of PARP and Caspase-3
( Supplementary Fig S1) . We concluded that XPO1 suppression abrogates the function of MYC oncogene and induces mass apoptosis in DHL tumor cells.
XPO1 has been reported to mediate nuclear export of several mRNAs encoding oncoproteins, including MYC, BCL2, and PIM1. Therefore, XPO1 inhibition may potentially reduce MYC protein expression through the nuclear retention of MYC mRNA. To test whether XPO1 inhibition affects nuclear export of MYC mRNA, we examined the distribution of MYC transcripts by cellular fractionation followed by quantitative realtime PCR. Compartmental separation of the nuclear versus cytoplasmic fractions was well achieved as shown by quantification of GAPDH and laminin B1 proteins, and Neat1 transcript in each compartment [18] ( Supplementary Fig S2C-D) . Interestingly, MYC nuclear to cytoplasmic ratio decreased by 50% upon XPO1 inhibition, while its mRNA abundance in the whole cell extract increased by two folds (Fig 1F-G) . The nuclear to cytoplasmic ratio of BCL2 but BCL6 increased modestly at 16 hours of posttreatment. The level and nuclear/cytoplasmic ratio of beta-actin, used as an internal control, was not affected by XPO1 inhibition (Supplementary Fig S2A-D) . This observation indicates that XPO1 inhibition may not result in a preferential nuclear retention of MYC mRNA. Therefore, the drastic downregulation of MYC protein expression upon XPO1 inhibition cannot be explained by changes in the levels and/or transport of MYC mRNA. We further ruled out the role of protein degradation as a contributing factor, as treatment with a proteasome inhibitor, carfilzomib, did not affect MYC shutdown by XPO1 inhibition (Supplementary Fig S2E) . Taken together, these data strongly suggest that the effective downregulation of MYC protein by XPO1 inhibition may occur at the level of protein translation.
XPO1 inhibition synergizes with BCL2 inhibition in vitro in killing DHL tumor cells
The compelling downregulation of MYC protein expression by XPO1 inhibition suggests the possibility to target MYC and BCL2 driver oncogenes in DHL by combining XPO1 and BCL2 inhibitors. To test this notion, we first determined the IC50 values for two targeted agents, ABT199 (a BCL2 inhibitor), and KPT8602 (an XPO1 inhibitor) in a panel of DHL cell lines. Among the DHL cell lines examined, some were resistant to ABT199 treatment, while others were moderately resistant to KPT8602.
However, to our surprise, none of the DHL cell lines were resistant to both, lending experimental support to the combinatorial use of XPO1 and BCL2 inhibitors to eradicate DHL tumor cells (Fig 2A-C , Supplementary Fig S3A-B) . Further in vitro examination of the drug combination using additional DHL cell lines demonstrated a strong synergy in cell death induction (Fig 3A, Supplementary Fig   S3C-D) , while treatment with single agent showed moderate effects. The apoptotic event resulting from the combined treatment was accompanied by enhanced PARP and Caspase 3 cleavage compared to treatment with either single agents (Fig 3B-D) . The apoptosis phenotype induced by synergistic drug combination was further confirmed by flow cytometric analysis following 7AAD/Annexin V staining ( Fig 3E) . MCL1 is known to play an important role in regulating the sensitivity of tumor cells to BCL2 inhibitors as MCL1 overexpression is associated with resistance to ABT199 [19, 20] . Next, we examined whether XPO1 inhibition enhances the sensitivity of tumors cells to ABT199 by downregulating MCL1. Indeed, MCL1 downregulation was observed in 8 out of 12 DHL cell lines treated with XPO1 inhibitor KPT8602 (Supplementary Fig S1A) . In DHL6 cells, the drug combination did not decrease MCL1 protein level but induced BIM protein expression ( Supplementary Fig S4A-C) .
These observations may explain the synergistic effect between XPO1 and BCL2 inhibitors in inducing apoptosis of DHL tumor cells.
Combined targeting of XPO1 and BCL2 blocks tumor progression and spread in vivo
Encouraged by our in vitro results, we initiated an in vivo study to test the combination therapy. Primary DHL patient-derived xenograft (PDX) tumor cells obtained from the Public Repository of Xenografts (PRoXe) were transplanted in NOD/SCID/IL2R gamma (NSG) mice [21] . These PDX tumor cells were labeled with firefly luciferase for bioluminescence imaging (BLI). Importantly, as part of the therapeutic regimen, a low dose of KPT8602 (7.5mg/kg, half of dose used in other studies) was used [13] [14] [15] . Additionally, at the start of the treatment, the tumor loads were at least 5 folds higher than recommended [21, 22] . Despite the low drug dose and higher than recommended tumor loads, we obtained a significant therapeutic response (Fig 4, Supplementary Fig S5) . The combined treatment completely blocked tumor progression and significantly extended survival, while single agents were only moderately effective (Fig 4A-C) . Importantly, BLI signals from the skulls were reduced by 22
folds indicating the drug treatment effectively blocks tumor metastasis to brain (Fig 4B, 4D) . Tumor samples were also collected 5 days after drug treatment for immunohistochemical analysis of MYC expression, tumor cell proliferation, and apoptosis (Ki67 and cleaved Caspase 3). The combined drug treatment drastically abrogated MYC protein expression, decreased tumor cell proliferation and induced apoptosis (Fig 4E) . Thus, combined targeting of XPO1 and BCL2 is highly effective for the treatment of human DHL in vivo.
Discussion:
XPO1 inhibition is a potential strategy to target MYC oncogene in DHL tumors as XPO1 inhibitors effectively downregulate MYC protein expression and reprogram the gene expression of MYC downstream targets. The mechanism by which XPO1 inhibition abolishes MYC protein expression remains unknown. We found that neither the expression nor the transport of MYC transcript can explain the downregulation of MYC expression by XPO1. Protein degradation as a contributing factor was also ruled out as proteasome inhibition did not rescue the downregulation of MYC by XPO1 inhibitors. Compared to other types of B-cell lymphomas, DHL tumors are more likely to spread to a patient's central nervous system (CNS) [24] . Brain involvement in lymphoma patients generally confers a more abysmal prognosis with a median survival of 2-5 months [24] . Our in vivo study with human PDX reveals that combined targeting of XPO1 and BCL2 blocks brain metastasis of DHL tumors. Thus, it may be possible to prevent tumor spread using this type of combination targeted therapy. Our finding is in concordance with a recent case report, where the use of another XPO1 inhibitor, selinexor (KPT330), was shown to restrain the CNS relapse in one DLBCL patient [25] . The role of XPO1 in brain metastasis and the notion of using XPO1 inhibitors to suppress CNS involvement of lymphoma may warrant further preclinical examination. β -actin was used as a loading control. 
Figure Legends
Figure S3
Figure S5
BLI images of tumor-bearing mice following drug treatments. Control mice were imaged at 15 days of treatment. Drug-treated mice were imaged at 21 days of treatments. 
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